ArticleInfection and drug resistance2025
BK Polyomavirus Prevalence in Renal Diseases: Associations with Immunosuppressants and Lymphocyte Subsets.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: BK polyomavirus (BKV), a latent pathogen in immunocompromised individuals, poses significant risks in renal-associated diseases (RD). Methods: This study recruited 88 healthy control (HC) individuals and 271 patients with RD, including 96 connective tissue diseases with renal involvement (CTD-RI), 90 chronic kidney disease (CKD), 66 urological tumors (UT), 19 kidney transplantation (KT), at Peking Union Medical College Hospital from January 2020 to September 2021. The BKV-DNA qPCR detection kit was evaluated in terms of lowest detection limit, linear range, accuracy, precision, analytical specificity. Urine, serum, and plasma specimens from 17 UT patients were detected simultaneously to evaluate the detection sensitivity of various sample types. The positive rates and loads of BKV-DNA were compared among the various groups. The difference in immunosuppressants use between BKV-DNA positive and negative groups was compared in patients with CTD-RI. Furthermore, the correlations between BKV-DNA loads and the counts of lymphocyte subsets were explored in the CTD-RI group. Results: The BKV-DNA qPCR detection kit has satisfactory sensitivity, linear range, reproducibility, accuracy, and specificity to detect the presence and loads of BKV-DNA. Urine specimens are more sensitive for BKV-DNA detection than serum and plasma. The CTD-RI and UT groups had higher BKV-DNA positive rates (49.0% and 31.8%, respectively) and loads (median: 5.69 log10 copies/mL and 6.03 log10 copies/mL, respectively) compared to the HC group (positive rate 12.5%, load median 3.96 log10 copies/mL). Multivariate logistic regression analysis indicated that the use of mycophenolate mofetil (MMF) was associated with a reduced risk of BKV (odds ratio and 95% confidence interval: 0.27 (0.09-0.78), Conclusion: These findings support monitoring BKV-DNA in high-risk RD patients to guide immunosuppressant use and mitigate renal injury. Future long-term follow-up and multicenter large-scale cohort studies are necessary to further clarify the role of BKV in RD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.